Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound.

doi:10.1172/JCI134395

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound.

The Journal of clinical investigation - 1 Jun 2020

Cale Evan M, Bai Hongjun, Bose Meera, Messina Michael A, Colby Donn J, Sanders-Buell Eric, Dearlove Bethany, Li Yifan, Engeman Emily, Silas Daniel, O'Sullivan Anne Marie, Mann Brendan, Pinyakorn Suteeraporn, Intasan Jintana, Benjapornpong Khunthalee, Sacdalan Carlo, Kroon Eugène, Phanuphak Nittaya, Gramzinski Robert, Vasan Sandhya, Robb Merlin L, Michael Nelson L, Lynch Rebecca M, Bailer Robert T, Pagliuzza Amélie, Chomont Nicolas, Pegu Amarendra, Doria-Rose Nicole A, Trautmann Lydie, Crowell Trevor A, Mascola John R, Ananworanich Jintanat, Tovanabutra Sodsai, Rolland Morgane

Abstract excerpt

Infusion of the broadly neutralizing antibody VRC01 has been evaluated in individuals chronically infected with HIV-1. Here, we studied how VRC01 infusions affected viral rebound after cessation of antiretroviral therapy (ART) in 18 acutely treated and durably suppressed individuals. Viral rebound occurred in all individuals, yet VRC01 infusions modestly delayed rebound and participants who showed a faster decay...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chronic Disease

Share to env Gene Products, Human Immunodeficiency Virus

Share to Epitopes

Share to HIV-1

Share to HIV Antibodies

Share to HIV Infections

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 32182219
DOI: 10.1172/JCI134395
PMCID: PMC7259993

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound.PMID 32182219Read ↗

Recurrent mutations drive rapid HIV escape from two broadly neutralizing antibodies <i>in vivo</i>Semantic proximity Read ↗

Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 InfectionSemantic proximity Read ↗

Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent VorinostatSemantic proximity Read ↗

Recurrent mutations drive rapid HIV escape from two broadly neutralizing antibodies in vivo.Semantic proximity Read ↗

Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance.Semantic proximity Read ↗

HIV-1 latent reservoir size and diversity are stable following brief treatment interruption.Semantic proximity Read ↗

T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapySemantic proximity Read ↗

Characterizing the Relationship Between Neutralization Sensitivity and env Gene Diversity During ART Suppression.Semantic proximity Read ↗

Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targeting: the RV217 acute infection cohort studySemantic proximity Read ↗

HIV superinfection reveals sequential reservoir reactivation and immune-driven rebound dynamicsSemantic proximity Read ↗

Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trialSemantic proximity Read ↗

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.